MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial
Titel:
MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial
Auteur:
Vermersch, Patrick Arnold, Douglas L Wolinsky, Jerry Havrdova, Eva Kubala Kinkolykh, Anastasiia Hyvert, Yann Tomic, Davorka Montalban, Xavier